These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38857463)

  • 1. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
    Leighl NB; Akamatsu H; Lim SM; Cheng Y; Minchom AR; Marmarelis ME; Sanborn RE; Chih-Hsin Yang J; Liu B; John T; Massutí B; Spira AI; Lee SH; Wang J; Li J; Liu C; Novello S; Kondo M; Tamiya M; Korbenfeld E; Moskovitz M; Han JY; Alexander M; Joshi R; Felip E; Voon PJ; Danchaivijitr P; Hsu PC; Silva Melo Cruz FJ; Wehler T; Greillier L; Teixeira E; Nguyen D; Sabari JK; Qin A; Kowalski D; Şendur MAN; Xie J; Ghosh D; Alhadab A; Haddish-Berhane N; Clemens PL; Lorenzini P; Verheijen RB; Gamil M; Bauml JM; Baig M; Passaro A;
    J Clin Oncol; 2024 Jun; ():JCO2401001. PubMed ID: 38857463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
    Passaro A; Wang J; Wang Y; Lee SH; Melosky B; Shih JY; Wang J; Azuma K; Juan-Vidal O; Cobo M; Felip E; Girard N; Cortot AB; Califano R; Cappuzzo F; Owen S; Popat S; Tan JL; Salinas J; Tomasini P; Gentzler RD; William WN; Reckamp KL; Takahashi T; Ganguly S; Kowalski DM; Bearz A; MacKean M; Barala P; Bourla AB; Girvin A; Greger J; Millington D; Withelder M; Xie J; Sun T; Shah S; Diorio B; Knoblauch RE; Bauml JM; Campelo RG; Cho BC;
    Ann Oncol; 2024 Jan; 35(1):77-90. PubMed ID: 37879444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amivantamab plus Lazertinib in Previously Untreated
    Cho BC; Lu S; Felip E; Spira AI; Girard N; Lee JS; Lee SH; Ostapenko Y; Danchaivijitr P; Liu B; Alip A; Korbenfeld E; Mourão Dias J; Besse B; Lee KH; Xiong H; How SH; Cheng Y; Chang GC; Yoshioka H; Yang JC; Thomas M; Nguyen D; Ou SI; Mukhedkar S; Prabhash K; D'Arcangelo M; Alatorre-Alexander J; Vázquez Limón JC; Alves S; Stroyakovskiy D; Peregudova M; Şendur MAN; Yazici O; Califano R; Gutiérrez Calderón V; de Marinis F; Passaro A; Kim SW; Gadgeel SM; Xie J; Sun T; Martinez M; Ennis M; Fennema E; Daksh M; Millington D; Leconte I; Iwasawa R; Lorenzini P; Baig M; Shah S; Bauml JM; Shreeve SM; Sethi S; Knoblauch RE; Hayashi H;
    N Engl J Med; 2024 Jun; ():. PubMed ID: 38924756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
    Felip E; Cho BC; Gutiérrez V; Alip A; Besse B; Lu S; Spira AI; Girard N; Califano R; Gadgeel SM; Yang JC; Yamamoto S; Azuma K; Kim YJ; Lee KH; Danchaivijitr P; Ferreira CG; Cheng Y; Sendur MAN; Chang GC; Wang CC; Prabhash K; Shinno Y; Stroyakovskiy D; Paz-Ares L; Rodriguez-Cid JR; Martin C; Campelo MRG; Hayashi H; Nguyen D; Tomasini P; Gottfried M; Dooms C; Passaro A; Schuler M; Gelatti ACZ; Owen S; Perdrizet K; Ou SI; Curtin JC; Zhang J; Gormley M; Sun T; Panchal A; Ennis M; Fennema E; Daksh M; Sethi S; Bauml JM; Lee SH
    Ann Oncol; 2024 Sep; 35(9):805-816. PubMed ID: 38942080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations.
    Petrini I; Giaccone G
    Onco Targets Ther; 2022; 15():1197-1210. PubMed ID: 36246734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
    Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amivantamab plus Chemotherapy in NSCLC with
    Zhou C; Tang KJ; Cho BC; Liu B; Paz-Ares L; Cheng S; Kitazono S; Thiagarajan M; Goldman JW; Sabari JK; Sanborn RE; Mansfield AS; Hung JY; Boyer M; Popat S; Mourão Dias J; Felip E; Majem M; Gumus M; Kim SW; Ono A; Xie J; Bhattacharya A; Agrawal T; Shreeve SM; Knoblauch RE; Park K; Girard N;
    N Engl J Med; 2023 Nov; 389(22):2039-2051. PubMed ID: 37870976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
    Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J
    Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience].
    Wang J; Chi Y; Chen H; Jia B; Zhai X; Ma M; Li J; Zhuo M
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):493-500. PubMed ID: 35899447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
    Cho BC; Kim DW; Spira AI; Gomez JE; Haura EB; Kim SW; Sanborn RE; Cho EK; Lee KH; Minchom A; Lee JS; Han JY; Nagasaka M; Sabari JK; Ou SI; Lorenzini P; Bauml JM; Curtin JC; Roshak A; Gao G; Xie J; Thayu M; Knoblauch RE; Park K
    Nat Med; 2023 Oct; 29(10):2577-2585. PubMed ID: 37710001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
    Chul Cho B; Han JY; Hyeong Lee K; Lee YG; Kim DW; Joo Min Y; Kim SW; Kyung Cho E; Kim JH; Lee GW; Sook Lee S; Lee N; Young Wang J; Park H; Ahn MJ
    Lung Cancer; 2024 Apr; 190():107509. PubMed ID: 38432025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
    Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
    Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lazertinib versus Platinum-Based Chemotherapy with Epidermal Growth Factor Receptor (EGFR)-Positive Non-Small-Cell Lung Cancer after Failing EGFR-Tyrosine Kinase Inhibitor: A Real-World External Comparator Study.
    Lee J; Lee H; Yoon D; Choi EY; Woo J; Jo B; Kim S; Shin JY; Jung HA
    Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC).
    Choi DH; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Lee SH
    Transl Lung Cancer Res; 2023 Dec; 12(12):2448-2459. PubMed ID: 38205202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.
    Lee KH; Cho BC; Ahn MJ; Lee YG; Lee Y; Lee JS; Kim JH; Min YJ; Lee GW; Lee SS; Lee KH; Ko YH; Shim BY; Kim SW; Shin SW; Choi JH; Kim DW; Cho EK; Park KU; Kim JS; Chun SH; Wang J; Choi S; Kang JH
    Cancer Res Treat; 2024 Jan; 56(1):48-60. PubMed ID: 37402411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With
    Cho BC; Ahn MJ; Kang JH; Soo RA; Reungwetwattana T; Yang JC; Cicin I; Kim DW; Wu YL; Lu S; Lee KH; Pang YK; Zimina A; Fong CH; Poddubskaya E; Sezer A; How SH; Danchaivijitr P; Kim Y; Lim Y; An T; Lee H; Byun HM; Zaric B
    J Clin Oncol; 2023 Sep; 41(26):4208-4217. PubMed ID: 37379502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
    Park K; Sabari JK; Haura EB; Shu CA; Spira A; Salgia R; Reckamp KL; Sanborn RE; Govindan R; Bauml JM; Curtin JC; Xie J; Roshak A; Lorenzini P; Millington D; Thayu M; Knoblauch RE; Cho BC
    Lung Cancer; 2023 Apr; 178():166-171. PubMed ID: 36868177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
    Brazel D; Nagasaka M
    Lung Cancer (Auckl); 2024; 15():41-47. PubMed ID: 38633373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
    Reungwetwattana T; Cho BC; Lee KH; Pang YK; Fong CH; Kang JH; Lee YG; Lim CS; Danchaivijitr P; Lim YN; Lee Y; How SH; Geater S; Lee SS; Min YJ; Kim JH; Lee JS; Lee GW; Soo RA; Lee SY; Choi S; Ahn MJ
    J Thorac Oncol; 2023 Oct; 18(10):1351-1361. PubMed ID: 37702629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy.
    Shah V; McNatty A; Simpson L; Ofori H; Raheem F
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.